Global research hotspots and research trends on idiopathic pulmonary fibrosis: a bibliometric and visualization analysis

被引:9
作者
Ma, Yue [1 ]
Zhou, Renyi [2 ]
Wu, Qiong [3 ]
机构
[1] China Med Univ, Shengjing Hosp, Dept Pulm & Crit Care Med, Shenyang, Peoples R China
[2] China Med Univ, Hosp 1, Dept Orthopaed, Shenyang, Peoples R China
[3] China Med Univ, Shengjing Hosp, Dept Pediat, 36 Sanhao St, Shenyang 110004, Peoples R China
基金
中国博士后科学基金;
关键词
Bibliometric analysis; hotspots; idiopathic pulmonary fibrosis (IPF); nintedanib; pirfenidone; DIAGNOSIS;
D O I
10.21037/apm-21-1836
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Idiopathic pulmonary fibrosis (IPF) is a life-threatening disease, the progression of which current drug therapy cannot reverse. This study analyzed current research hotspots and future research trends in IPF through bibliometric methods, with the aim of providing a reference for new therapeutic strategies. Methods: Publications on IPF obtained from the Web of Science Core Collection database, The Literature Metrology Online Analysis Platform, and CiteSpace were used to analyze publication characteristics. VOSviewer was used to conduct keywords co-occurrence analysis and analyze research hotspots. Results: A total of 7,016 publications related to IPF were identified from 2011 to 2020. The most contributions were from the USA and the five research institutions with the largest number of publications were all from that country. The American Journal of Respiratory and Critical Care Medicine was the most cited journal and had an incontrovertible academic impact with five of the top 10 high-cited references published in this journal. G Raghu was the academic authority in this domain in terms of both the number of publications and the most citations. By analyzing keywords, we identified three IPF research hotspot clusters, which are "clinical research", "pathogenesis research" and "diagnosis research" respectively. Conclusions: We evaluated all publications concerning IPF research in the past decade through bibliometric analysis. The current research hotspot in this field is drug therapy for the condition using nintedanib and pirfenidone. Future research will focus on conducting multi-center randomized controlled trials to explore and evaluate new therapeutic drugs for IPF. It is hoped that this study can provide information and data support for further research and the development of new therapeutic drugs.
引用
收藏
页码:9057 / +
页数:19
相关论文
共 25 条
  • [1] Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases
    Cottin, Vincent
    Hirani, Nikhil A.
    Hotchkin, David L.
    Nambiar, Anoop M.
    Ogura, Takashi
    Otaola, Maria
    Skowasch, Dirk
    Park, Jong Sun
    Poonyagariyagorn, Hataya K.
    Wuyts, Wim
    Wells, Athol U.
    [J]. EUROPEAN RESPIRATORY REVIEW, 2018, 27 (150)
  • [2] Predictors of progression in systemic sclerosis patients with interstitial lung disease
    Distler, Oliver
    Assassi, Shervin
    Cottin, Vincent
    Cutolo, Maurizio
    Danoff, Sonye K.
    Denton, Christopher P.
    Distler, Jorg H. W.
    Hoffmann-Vold, Anna-Maria
    Johnson, Sindhu R.
    Ladner, Ulf Mueller
    Smith, Vanessa
    Volkmann, Elizabeth R.
    Maher, Toby M.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (05)
  • [3] Dong GZ, 2014, CHINESE J ELECTRON, V23, P695
  • [4] The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis
    Grimminger, Friedrich
    Guenther, Andreas
    Vancheri, Carlo
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 45 (05) : 1426 - 1433
  • [5] Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets
    Hewlett, Justin C.
    Kropski, Jonathan A.
    Blackwell, Timothy S.
    [J]. MATRIX BIOLOGY, 2018, 71-72 : 112 - 127
  • [6] A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
    King, Talmadge E., Jr.
    Bradford, Williamson Z.
    Castro-Bernardini, Socorro
    Fagan, Elizabeth A.
    Glaspole, Ian
    Glassberg, Marilyn K.
    Gorina, Eduard
    Hopkins, Peter M.
    Kardatzke, David
    Lancaster, Lisa
    Lederer, David J.
    Nathan, Steven D.
    Pereira, Carlos A.
    Sahn, Steven A.
    Sussman, Robert
    Swigris, Jeffrey J.
    Noble, Paul W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) : 2083 - 2092
  • [7] Idiopathic pulmonary fibrosis
    King, Talmadge E., Jr.
    Pardo, Annie
    Selman, Moises
    [J]. LANCET, 2011, 378 (9807) : 1949 - 1961
  • [8] Therapeutic targets in idiopathic pulmonary fibrosis
    Kolb, Martin
    Bonella, Francesco
    Wollin, Lutz
    [J]. RESPIRATORY MEDICINE, 2017, 131 : 49 - 57
  • [9] Idiopathic Pulmonary Fibrosis
    Lederer, David J.
    Martinez, Fernando J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) : 1811 - 1823
  • [10] Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper
    Lynch, David A.
    Sverzellati, Nicola
    Travis, William D.
    Brown, Kevin K.
    Colby, Thomas V.
    Galvin, Jeffrey R.
    Goldin, Jonathan G.
    Hansell, David M.
    Inoue, Yoshikazu
    Johkoh, Takeshi
    Nicholson, Andrew G.
    Knight, Shandra L.
    Raoof, Suhail
    Richeldi, Luca
    Ryerson, Christopher J.
    Ryu, Jay H.
    Wells, Athol U.
    [J]. LANCET RESPIRATORY MEDICINE, 2018, 6 (02) : 138 - 153